Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-03

AUTHORS

T J Vaughan, A J Williams, K Pritchard, J K Osbourn, A R Pope, J C Earnshaw, J McCafferty, R A Hodits, J Wilton, K S Johnson

ABSTRACT

To generate a stable resource from which high affinity human antibodies to any given antigen can be rapidly isolated, functional V-gene segments from 43 non-immunized human donors were used to construct a repertoire of 1.4 x 10(10) single-chain Fv (scFv) fragments displayed on the surface of phage. Fragments were cloned in a phagemid vector, enabling both phage displayed and soluble scFv to be produced without subcloning. A hexahistidine tag has been incorporated to allow rapid purification of scFv by nickel chelate chromatography. This library format reduces the time needed to isolate monoclonal antibody fragments to under two weeks. All of the measured binding affinities show a Kd < 10 nM and off-rates of 10(-3) to 10(-4) s-1, properties usually associated with antibodies from a secondary immune response. The best of these scFvs, an anti-fluorescein antibody (0.3 nM) and an antibody directed against the hapten DTPA (0.8 nM), are the first antibodies with subnanomolar binding affinities to be isolated from a naive library. Antibodies to doxorubicin, which is both immunosuppressive and toxic, as well as a high affinity and high specificity antibody to the steroid hormone oestradiol have been isolated. This work shows that conventional hybridoma technology may be superseded by large phage libraries that are proving to be a stable and reliable source of specific, high affinity human monoclonal antibodies. More... »

PAGES

309

Journal

TITLE

Nature Biotechnology

ISSUE

3

VOLUME

14

Author Affiliations

Related Patents

  • Targeted Gene Delivery To Non-Phagocytic Mammalian Cells Via Bacterially Derived Intact Minicells
  • Antibodies Directed Against Amyloid-Beta Peptide And Methods Using Same
  • Multiple Signaling Pathways Induced By Hexavalent, Monospecific And Bispecific Antibodies For Enhanced Toxicity To B-Cell Lymphomas And Other Diseases
  • Apo-2 Receptor Polypeptides
  • Nucleic Acids Encoding Antibodies Against Pd-1
  • Antibodies Directed Against Amyloid-Beta Peptide And Methods Using Same
  • High Affinity Fully Human Monoclonal Antibodies To Interleukin-8
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Antibodies To Tgfβ
  • Compositions Comprising Anti-Ceacam1 And Anti-Pd Antibodies For Cancer Therapy
  • Combination Immuno Therapy And Radiotherapy For The Treatment Of Her-2-Positive Cancers
  • Therapeutic Combination And Methods Of Treatment With A Dll4 Antagonist And An Anti-Hypertensive Agent
  • Methods For Treating Psoriasis Using Antibodies That Bind To The P40 Subunit Of Il-12 And/Or Il-23
  • Methods Of Delivering Dll3 Antibody Drug Conjugates
  • Anti-Interferon-Α Antibodies
  • Extracellular Matrix Metalloproteinase Inducer (Emmprin) Peptides And Binding Antibodies
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Fluorophore Chelated Lanthanide Luminescent Probes With Improved Quantum Efficiency
  • Anti-Vegf Antibodies
  • Compositions And Methods For Targeted In Vitro And In Vivo Drug Delivery To Mammalian Cells Via Bacterially Derived Intact Minicells
  • Therapeutic Combination And Methods Of Treatment With A Dll4 Antagonist And An Anti-Hypertensive Agent
  • Antibody Producing Non-Human Mammals
  • Hydrophilic Self-Immolative Linkers And Conjugates Thereof
  • Anti-Ccl17 Antibodies
  • Antibodies To Carcinoembryonic Antigen-Related Cell Adhesion Molecule (Ceacam)
  • Anti-Dll3 Antibody Drug Conjugates
  • Anti-Vegf Antibodies
  • Recombinant Production Of Mixtures Of Antibodies
  • Method For Making Monoclonal Antibodies And Cross-Reactive Antibodies Obtainable By The Method
  • Neutralizing Anti-Ccl20 Antibodies
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Fluorophore Chelated Lanthanide Luminescent Probes With Improved Quantum Efficiency
  • Wsx Receptor Agonist Antibodies
  • Compositions And Methods Comprising Klk3 Or Folh1 Antigen
  • Antibodies To Amyloid Beta
  • Notch1 Receptor Binding Agents And Methods Of Use Thereof
  • Method For Enhancing Proliferation Or Differentiation Of A Cell Using Ob Protein
  • Methods For Obtaining, Identifying And Applying Nucleic Acid Sequences And (Poly)Peptides Which Increase The Expression Yields Of Periplasmic Proteins In Functional Form
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Method For Making Multispecific Antibodies Having Heteromultimeric And Common Components
  • Methods And Means For The Production Of Ig-Like Molecules
  • Methods Of Treating Psoriasis By Administration Of Antibodies To The P40 Subunit Of Il-12 And/Or Il-23
  • Anti-Dll3 Antibodies
  • Dual Delivery System For Heterologous Antigens
  • Notch1 Binding Agents And Methods Of Use Thereof
  • Ddr1-Binding Agents And Methods Of Use Thereof
  • Method Of Modifying Isoelectric Point Of Antibody Via Amino Acid Substitution In Cdr
  • Anti-Dll3 Antibody Drug Conjugates
  • Treatment And Prevention Of Cancer With Hmgb1 Antagonists
  • Antibodies Against Human Or Mouse Il-21 Receptor
  • Antibodies Against Pd-1
  • Phenyl Glyoxal Probes
  • Polynucleotides Encoding Vegf/Dll4 Binding Agents
  • Human Antibodies Against Human Glycoprotein Vi And Their Use
  • A Method For Making Multispecific Antibodies Having Heteromultimeric And Common Components
  • Procedure For The Generation Of A High Producer Cell Line For The Expression Of A Recombinant Anti-Cd34 Antibody
  • Focused Libraries Of Genetic Packages
  • Production Of Proteins In Glutamine-Free Cell Culture Media
  • Isolated B7-H4 Specific Compositions And Methods Of Use Thereof
  • Focused Libraries Of Genetic Packages
  • Modulators Of Body Weight, Corresponding Nucleic Acids And Proteins
  • Stimulus Responsive Polymers For The Purification Of Biomolecules
  • Method For In Vitro Molecular Evolution Of Protein Function
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Alpha-Fetoprotein Immu31 Antibodies And Fusion Proteins And Methods Of Use Thereof
  • Neuropilin Antagonists
  • Histidine Engineered Light Chain Antibodies And Genetically Modified Non-Human Animals For Generating The Same
  • Isolated B7-H4 Specific Compositions And Methods Of Use Thereof
  • Methods For Inhibiting The Activity Of The P40 Subunit Of Human Il-12
  • Murine Antibody Display Library
  • Non-Desensitizing Mutant Of The Transient Receptor Potential Trpm5 Ion Channel
  • Isolation Of Binding Proteins With High Affinity To Ligands
  • Antibodies Against Protective Antigen
  • Transgenic Mammals Having Human Ig Loci Including Plural Vh And Vkappa Regions And Antibodies Produced Therefrom
  • Anti-Tissue Factor Antibodies And Methods Of Use Thereof
  • Methods For Treating Bone Cancer Pain By Administering A Nerve Growth Factor Antagonist Antibody
  • Compositions And Methods For Identifying Response Targets And Treating Flavivirus Infection Responses
  • Use Of Anti-Tissue Factor Antibodies For Treating Thromboses
  • Anti-Vegf Antibodies
  • Antibodies Directed Against Amyloid-Beta Peptide And Nucleic Acids Encoding Same
  • Antibodies For Inhibiting Blood Coagulation And Methods Of Use Thereof
  • Apo-2 Receptor Polypeptides
  • Antibodies To Tgf-Β
  • Combination Therapy With Anti-Cd74 Antibodies Provides Enhanced Toxicity To Malignancies, Autoimmune Disease And Other Diseases
  • Binding Polypeptides And Uses Thereof
  • Focused Libraries Of Genetic Packages
  • Methods Of Obtaining A Specific Binding Member That Binds Eotaxin
  • Neuropilin Antagonists
  • Internalizing Erbb2 Antibodies
  • Carbonic Anhydrase Ix (G250) Anitbodies
  • Anti-Ngf Antibodies And Methods Using Same
  • Antibodies To Il-1 R1 And Methods Of Making Them
  • Optimized Variants Of Anti-Vegf Antibodies And Methods Of Treatment Thereof By Reducing Or Inhibiting Angiogenesis
  • Methods For Producing Polypeptides By Regulating Polypeptide Association
  • Methods Of Delivering Dll3 Antibody Drug Conjugates
  • Focused Libraries Of Genetic Packages
  • Use Of T1r3 Venus Flytrap Region Polypeptide To Screen For Taste Modulators
  • Anti-Dll3 Antibody Drug Conjugates And Methods Of Use
  • Antibodies To Tgf-Beta
  • Antibodies Recognizing A Carbohydrate Containing Epitope On Cd-43 And Cea Expressed On Cancer Cells And Methods Using Same
  • Nucleic Acids Encoding Neutralizing Anti-Ccl20 Antibodies
  • Human Antibodies That Bind The P40 Subunit Of Human Il-12 And Methods For Using The Same
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Peptide And Antibody Libraries And Uses Thereof
  • Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)
  • Hydrophilic Self-Immolative Linkers And Conjugates Thereof
  • Method For Treating Cancer Using An Antibody That Inhibits Notch4 Signaling
  • Reversible Immobilization Of Arginine-Tagged Moieties On A Silicate Surface
  • Generation Of Specific Binding Partners Binding To (Poly)Peptides Encoded By Genomic Dna Fragments Or Ests
  • Dual-Tagged Proteins And Their Uses
  • Assays For The Detection Of Microtubule Depolymerization Inhibitors
  • Cellular Vaccines And Immunotherapeutics And Methods For Their Preparation
  • Method For Making Monoclonal Antibodies And Cross-Reactive Antibodies Obtainable By The Method
  • Labelling And Selection Of Molecules
  • Recombinant Production Of Mixtures Of Antibodies
  • Compositions And Methods For Diagnosing And Treating Cancer
  • Anti-Vegf Antibodies
  • Anti-Mesothelin Antibodies
  • Compositions And Methods For Identifying Response Targets And Treating Flavivirus Infection Responses
  • Antibody Substituting For Function Of Blood Coagulation Factor Viii
  • Dock-And-Lock (Dnl) Complexes For Therapeutic And Diagnostic Use
  • Anti-Dll3 Antibody Drug Conjugates
  • Methods For Diagnosis And Treatment Of Endometrial Cancer
  • Methods For Treating Psoriasis By Administering An Antibody Which Binds An Epitope Of The P40 Subunit Of Il-12 And/Or Il-23
  • Histidine Engineered Light Chain Antibodies And Genetically Modified Non-Human Animals For Generating The Same
  • Monoclonal Antibodies To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)
  • Deletions In Domain Ii Of Pseudomonas Exotoxin A That Remove Immunogenic Epitopes
  • Antibodies Directed To Angiopoietin-1 And Angiopoietin-2 And Uses Thereof
  • Antibodies To A Non-Ligand Binding Region Of At Least Two Notch Receptors
  • Non-Human Animals Expressing Ph-Sensitive Immunoglobulin Sequences
  • Small Molecules That Replace Or Agonize P53 Function
  • Inhibition Of The Tumorigenic Potential Of Tumor Stem Cells By Lif And Bmps
  • Notch1 Receptor Antibodies And Methods Of Treatment
  • Polynucleotides Encoding Notch Receptor Antibodies
  • Kits Containing Dll3 Antibody Drug Conjugates
  • Anti-Cxcr4 Antibodies And Antibody-Drug Conjugates
  • Anti-Glucosaminidase Passive Immunization For Staphylococcus Aureus Infections
  • Vegf Binding Antibodies
  • Methods For Treating Headache Using Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide
  • Method For Making Heteromultimeric Molecules
  • Modified Immunoglobulin Molecules That Specifically Bind Human Vegf And Dll4
  • Method For Making Multispecific Antibodies Having Heteromultimeric And Common Components
  • Lim Kinasemodulating Agents For Neurofibromatoses Therapy And Methods For Screening For Same
  • Decreasing Lactate Level And Increasing Polypeptide Production By Downregulating The Expression Of Lactate Dehydrogenase And Pyruvate Dehydrogenase Kinase
  • Assay For Measurement Of Antibodies Binding To A Therapeutic Monoclonal Antibody
  • Multiple Signaling Pathways Induced By Hexvalent, Monospecific And Bispecific Antibodies For Enhanced Toxicity To B-Cell Lymphomas And Other Diseases
  • Nucleic Acid Molecule Encoding A Specific Il-1r1 Antibody
  • Human Antibodies That Bind Human Interleukin-12
  • Compositions And Methods For Diagnosing And Treating Cancer
  • Antibody Substituting For Function Of Blood Coagulation Factor Viii
  • Antibodies Directed To Angiopoietin-1 And Angiopoietin-2 And Uses Thereof
  • Small Molecules That Replace Or Agonize P53 Function
  • Antibodies To A Non-Ligand Binding Region Of At Least Two Notch Receptors
  • Methods For Treating Psoriasis By Administering An Antibody Which Binds An Epitope Of The P40 Subunit Of Il-12 And/Or Il-23
  • Dock-And-Lock (Dnl) Complexes For Therapeutic And Diagnostic Use
  • Histidine Engineered Light Chain Antibodies And Genetically Modified Non-Human Animals For Generating The Same
  • Non-Human Animals Expressing Ph-Sensitive Immunoglobulin Sequences
  • Labelling And Selection Of Molecules
  • Use Of Listeria Vaccine Vectors To Reverse Vaccine Unresponsiveness In Parasitically Infected Individuals
  • Antibody That Binds Murine Wise Protein
  • Recombinant Production Of Mixtures Of Antibodies
  • Internalizing Erbb2 Antibodies
  • Antibodies Recognizing A Carbohydrate Containing Epitope On Cd-43 And Cea Expressed On Cancer Cells And Methods Using Same
  • Anti-Cd26 Antibodies And Methods Of Use Thereof
  • Antibodies Directed To Angiopoietin-1 And Angiopoietin-2 And Uses Thereof
  • Chimeric T1r Taste Receptor Polypeptides And Nucleic Acid Sequences Encoding And Cell Lines That Express Said Chimeric T1r Polypeptides
  • T1r3 Transgenic Animals, Cells And Related Methods
  • High Throughput Screening Assay For The Trpm5 Ion Channel
  • Apo-2 Receptor Polynucleotides
  • Method For Making Multispecific Antibodies Having Heteromultimeric And Common Components
  • Anti-Vegf Antibodies
  • Anti-Ngf Antibodies And Methods Using Same
  • Sirt4 Activities
  • Reversible Immobilization Of Arginine-Tagged Moieties On A Silicate Surface
  • Recombinant Production Of Mixtures Of Antibodies
  • Dual-Tagged Proteins And Their Uses
  • Assays For The Detection Of Microtubule Depolymerization Inhibitors
  • Cellular Vaccines And Immunotherapeutics And Methods For Their Preparation
  • Method For Making Monoclonal Antibodies And Cross-Reactive Antibodies Obtainable By The Method
  • Generation Of Specific Binding Partners Binding To (Poly)Peptides Encoded By Genomic Dna Fragments Or Ests
  • Polynucleotides Encoding Antibodies Directed Against Amyloid-Beta Peptide
  • Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)
  • Peptide And Antibody Libraries And Uses Thereof
  • Hydrophilic Self-Immolative Linkers And Conjugates Thereof
  • Method For Treating Cancer Using An Antibody That Inhibits Notch4 Signaling
  • Flavors, Flavor Modifiers, Tastants, Taste Enhancers, Umami Or Sweet Tastants, And/Or Enhancers And Use Thereof
  • Suppressor Cell Function Inhibition Following Listeria Vaccine Treatment
  • Anti-Dll3 Antibody Drug Conjugates And Methods Of Use
  • Nucleic Acids Encoding Neutralizing Anti-Ccl20 Antibodies
  • Human Antibodies That Bind The P40 Subunit Of Human Il-12 And Methods For Using The Same
  • Deletions In Domain Ii Of Pseudomonas Exotoxin A That Remove Immunogenic Epitopes
  • Methods For Identifying And Isolating Cells Expressing A Polypeptide
  • Monoclonal Antibodies To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Anti-Cxcr4 Antibodies And Antibody-Drug Conjugates
  • Kits Containing Dll3 Antibody Drug Conjugates
  • Anti-Dll3 Antibody Drug Conjugates
  • Methods For Diagnosis And Treatment Of Endometrial Cancer
  • Anti-Vegf Antibodies
  • Anti-Mesothelin Antibodies
  • Compositions And Methods For Identifying Response Targets And Treating Flavivirus Infection Responses
  • Anti-Glucosaminidase Passive Immunization For Staphylococcus Aureus Infections
  • Inhibition Of The Tumorigenic Potential Of Tumor Stem Cells By Lif And Bmps
  • Notch1 Receptor Antibodies And Methods Of Treatment
  • Polynucleotides Encoding Notch Receptor Antibodies
  • Methods For Identifying And Isolating Cells Expressing A Polypeptide
  • Anti-Neuropilin Antibodies And Methods Of Use
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Methods For Identifying And Isolating Cells Expressing A Polypeptide
  • Method For Making Multispecific Antibodies Having Heteromultimeric And Common Components
  • Bacterial Virulence Factors And Uses Thereof
  • Anti-Interferon-Α Antibodies
  • Pseudomonas Exotoxin A With Reduced Immunogenicity
  • Focused Libraries Of Genetic Packages
  • Non-Human Animals Expressing Ph-Sensitive Immunoglobulin Sequences
  • Dock-And-Lock (Dnl) Complexes For Therapeutic And Diagnostic Use
  • Humanized Anti-Tgf-Beta Antibodies
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Alpha-Fetoprotein Immu31 Antibodies And Fusion Proteins And Methods Of Use Thereof
  • Methods For Identifying Agents That Alter Nad-Dependent Deacetylation Activity Of A Sir2 Protein
  • Method And Kit For Generating High Affinity Binding Agents
  • Anti-Dll3 Antibody Drug Conjugates And Methods Of Use
  • Anti-Folate Receptor Alpha (Fra) Antibody-Drug Conjugates And Methods Of Using Thereof
  • Antibody Producing Non-Human Mammals
  • Monoclonal Antibody That Binds Human Notch2 And Notch3
  • Chimeric T1r Taste Receptor Polypeptides And Nucleic Acid Sequences Encoding And Cell Lines That Express Said Chimeric T1r Polypeptides
  • Mixture Of Binding Proteins
  • Artificial Human Chromosome Containing Human Antibody A Light Chain Gene
  • Direct Screening Method
  • Combination Therapy With Anti-Cd74 Antibodies Provides Enhanced Toxicity To Malignancies, Autoimmune Disease And Other Diseases
  • Anti-Glucosaminidase Passive Immunization For Staphylococcus Aureus Infections
  • Neuropilin Antagonists
  • Small Molecules That Replace Or Agonize P53 Function
  • Methods And Monitoring Of Treatment With A Dll4 Antagonist
  • Anti-Dll3 Antibodies
  • Human Monoclonal Antibody To The Human Epidermal Growth Factor Receptor
  • Anti-Vegf Antibodies
  • Anti-Interferon-Α Antibodies
  • Essential Genes Of Yeast As Targets For Antifungal Agents, Herbicides, Insecticides And Anti-Proliferative Drugs
  • Listeria-Based Adjuvants
  • Anti-Cgrp Compositions And Use Thereof
  • Polynucleotides Encoding Anti-Notch1 Nrr Antibody Polypeptides
  • Decreasing Lactate Level And Increasing Polypeptide Production By Downregulating The Expression Of Lactate Dehydrogenase And Pyruvate Dehydrogenase Kinase
  • Immunological Targeting Of Pathological Tau Proteins
  • Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
  • Combinatorial Protein Library Screening By Periplasmic Expression
  • Uncoupling Of Dna Insert Propagation And Expression Of Protein For Phage Display
  • Identification Of Target Structures E.G. In Vivo Selection Method For A Phage Library
  • Method For Screening For Drug Candidates For Modulating Transcription Factor Activity
  • Method, Array And Kit For Detecting Activated Transcription Factors By Hybridization Array
  • Biomarker Of Asbestos Exposure And Mesothelioma
  • Methods For Treating Melanoma
  • Anti-Dll3 Antibody Drug Conjugates
  • Listeria-Based Adjuvants
  • Method For Selecting A Single Cell Expressing A Heterogeneous Combination Of Antibodies
  • Nucleic Acid Encoding Dll3 Antibodies
  • Antibodies To The C3d Fragment Of Complement Component 3
  • Antibodies To Tgf-Β
  • Methods Of Modifying Antibodies For Purification Of Bispecific Antibodies
  • Antibodies Which Bind To Epithelial Membrane Protein 2 (Emp2)
  • Anti-Dll3 Antibody Drug Conjugates And Methods Of Use
  • Enhancing Activity Of Car T Cells By Co-Introducing A Bispecific Antibody
  • Multiple Signaling Pathways Induced By Hexavalent, Monospecific And Bispecific Antibodies For Enhanced Toxicity To B-Cell Lymphomas And Other Diseases
  • Method Of Modifying Isoelectric Point Of Antibody Via Amino Acid Substitution In Cdr
  • Compositions And Methods For Treating And Diagnosing Pancreatic Cancer
  • Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide
  • Non-Affinity Purification Of Proteins
  • Use Of A Decoy Protein That Interferes With The Hedgehog Signalling Pathway For The Manufacture Of A Medicament For Preventing, Inhibiting, And/Or Reversing Ocular Diseases Related With Ocular Neovascularization
  • Transgenic Mammals Having Human Ig Loci Including Plural Vh And Vk Regions And Antibodies Produced Therefrom
  • Method For Obtaining Antibodies
  • Met-Binding Agents And Uses Thereof
  • Chimeric T Cell Receptor Comprising Carbonic Anhydrase Ix (G250) Antibody
  • Multivalent Dll3 Antibodies
  • Method For Detecting Transcription Factor-Protein Interactions
  • Methods For Treating Headache Using Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide
  • Compositions And Methods For Diagnosing And Treating Cancer
  • Anti-Dll3 Antibody Drug Conjugates
  • Methods Of Making Dll3 Antibody Drug Conjugates
  • Internalizing Erbb2 Antibodies
  • Methods For Identifying And Isolating Cells Expressing A Polypeptide
  • Polynucleotides Encoding Notch1 Receptor Antibodies
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Nucleic Acids Encoding Modulators Of Body Weight
  • Method For Isolating Bdca-4+ Dendritic Cells
  • Methods For Treating Pain By Administering A Nerve Growth Factor Antagonist And An Nsaid
  • Methods Of Treating Cancer By Administering Emp2 Antibodies
  • Stirred Tank Bioreactor
  • Flavors, Flavor Modifiers, Tastants, Taste Enhancers, Umami Or Sweet Tastants, And/Or Enhancers And Use Thereof
  • Mutated Pseudomonas Exotoxins With Reduced Antigenicity
  • T1r Hetero-Oligomeric Taste Receptors, Cell Lines That Express Said Receptors, And Taste Compounds
  • Sir2 Activity
  • Assays For Detecting Modulators Of Cytoskeletal Function
  • Antibodies For Cancer Therapy And Diagnosis
  • Variable Heavy Chain And Variable Light Chain Regions Of Antibodies To Human Platelet Glycoprotein Ib Alpha
  • Anti-Cd74 Immunoconjugates And Methods
  • Site-Specific Antibody Conjugation Methods And Compositions
  • Use Of Anti-Cgrp Antibodies And Antibody Fragments To Treat Diarrhea In Subjects With Diseases Or Treatments That Result In Elevated Cgrp Levels
  • Methods Of Making Dll3 Antibody Drug Conjugates
  • Anti-Dll3 Antibody Drug Conjugates
  • Anti-Dll3 Antibody Drug Conjugates
  • Cytotoxicity-Inducing Theraputic Agent
  • Anti-Cgrp Compositions And Use Thereof
  • Anti-Dll3 Antibody Drug Conjugates
  • Peptidic Chimeric Antigen Receptor T Cell Switches And Uses Thereof
  • Crystalline Anti-Human Il-12 Antibodies
  • Alpha-Fetoprotein Immu31 Antibodies And Fusion Proteins And Methods Of Use Thereof
  • Human Alpha-Folate Receptor Chimeric Antigen Receptor
  • Compositions And Methods For Treating And Diagnosing Pancreatic Cancer
  • Methods Of Obtaining A Specific Binding Member That Binds Eotaxin
  • Antibodies To Tgf-Β
  • Enhanced Protein Purification Through A Modified Protein A Elution
  • Methods Of Detection, Diagnosis, And Monitoring Using Anti-Dll3 Antibodies
  • Chimeric T1r Taste Receptor Polypeptides And Nucleic Acid Sequences Encoding And Cell Lines That Express Said Chimeric T1r Polypeptides
  • Recombinant Production Of Mixtures Of Antibodies
  • Fully Human, Anti-Mesothelin Specific Chimeric Immune Receptor For Redirected Mesothelin-Expressing Cell Targeting
  • Antibodies That Block Receptor Protein Tyrosine Kinase Activation, Methods Of Screening For And Uses Thereof
  • Method Of Treating Cancer By Administering A Monoclonal Antibody That Binds Human Notch2 And Notch3
  • Neuropilin Antagonists
  • Polypeptides For The Detection Of Microtubule Depolymerization Inhibitors
  • Nucleic Acids Encoding A Katanin P60 Subunit
  • Labelling And Selection Of Molecules
  • Essential Genes Of Yeast As Targets For Antifungal Agents, Herbicides, Insecticides And Anti-Proliferative Drugs
  • Antibodies Directed Against Amyloid-Beta Peptide
  • Variable Domain Library And Uses
  • Apo-2 Receptor Agonist Antibodies
  • Method For Selecting A Single Cell Expressing A Heterogeneous Combination Of Antibodies
  • Transgenic Mammals Having Human Ig Loci Including Plural Vh And Vkappa Regions And Antibodies Produced Therefrom
  • Synthetic Antibody Phage Libraries
  • Method For Using Antibodies For Inhibiting Blood Coagulation
  • Human Antibodies Interacting With Hiv Gp41
  • Anti-Vegf Antibodies
  • Screening Assay For Inhibitors Of Trpa1 Activation By A Lower Alkyl Phenol
  • Methods Of Making Dll3 Antibody Drug Conjugates
  • Antibody Producing Non-Human Mammals
  • Bacterial Virulence Factors And Uses Thereof
  • Methods Of Treating Plaque Psoriasis
  • Antibodies That Bind The Glutamate Ligand Binding Region Of Notch3
  • Anti-Vegf Antibodies
  • Method For Making Heteromultimeric Molecules
  • Antibodies Recognizing A Carbohydrate Containing Epitope On Cd-43 And Cea Expressed On Cancer Cells And Methods Using Same
  • Anti-Notch1 Nrr Antibodies
  • Crystalline Anti-Human Il-12 Antibodies
  • Conformation-Specific Anti-Von Willebrand Factor Antibodies
  • Comestible Compositions Comprising High Potency Savory Flavorants, And Processes For Producing Them
  • Fully Human Anti-Epidermal Growth Factor Receptor Antibodies
  • Production Of Proteins In Glutamine-Free Cell Culture Media
  • Anti-Cd74 Immunoconjugates And Methods
  • Hydrophilic Self-Immolative Linkers And Conjugates Thereof
  • Dual Delivery System For Heterologous Antigens
  • Method And Kit For Isolating Dna Probes That Bind To Activated Transcription Factors
  • Methods Of Treating Psoriasis By Administration Of Antibodies To The P40 Subunit Of Il-12 And/Or Il-23
  • Nucleic Acids Coding For Antibodies Against Human Il-21 Receptor And Uses Therefor
  • Assays And Kits For Detecting Protein Binding
  • Treatment Of Pancreatic Developmental Gene Related Diseases By Inhibition Of Natural Antisense Transcript To A Pancreatic Developmental Gene
  • Recombinant Production Of Mixtures Of Antibodies
  • A Method For Making Multispecific Antibodies Having Heteromultimeric And Common Components
  • Vegf/Dll4 Binding Agents And Uses Thereof
  • Internalizing Erb2 Antibodies
  • Anti-Dll3 Antibody Drug Conjugates
  • Anti-Pdgf-C Antibodies
  • Neutralizing Anti-Ccl20 Antibodies
  • Use Of Anti-Cgrp Antibodies And Antibody Fragments To Prevent Or Inhibit Photophobia Or Light Aversion In Subjects In Need Thereof, Especially Migraine Sufferers
  • Antibodies To Il-1r1
  • Focused Libraries Of Genetic Packages
  • Methods For Treating Bone Cancer By Administering A Nerve Growth Factor Antagonist Antibody
  • Anti-Vegf Antibodies
  • Anti-Vegf Antibodies
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nbt0396-309

    DOI

    http://dx.doi.org/10.1038/nbt0396-309

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1022704505

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/9630891


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Amino Acid Sequence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibody Affinity", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibody Specificity", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bacteriophages", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Base Sequence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biotechnology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cloning, Molecular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Doxorubicin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Estradiol", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunoglobulin Fragments", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "In Vitro Techniques", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kinetics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Molecular Sequence Data", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oligodeoxyribonucleotides", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "AstraZeneca (United Kingdom)", 
              "id": "https://www.grid.ac/institutes/grid.417815.e", 
              "name": [
                "Cambridge Antibody Technology Ltd., Unit B3, Melbourn, Cambridgeshire, U.K."
              ], 
              "type": "Organization"
            }, 
            "familyName": "Vaughan", 
            "givenName": "T J", 
            "id": "sg:person.0743122630.97", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743122630.97"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Williams", 
            "givenName": "A J", 
            "id": "sg:person.0632260431.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632260431.54"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Pritchard", 
            "givenName": "K", 
            "id": "sg:person.0700373631.57", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700373631.57"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Osbourn", 
            "givenName": "J K", 
            "id": "sg:person.01057320671.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057320671.34"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Pope", 
            "givenName": "A R", 
            "id": "sg:person.01014622231.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014622231.24"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Earnshaw", 
            "givenName": "J C", 
            "id": "sg:person.0746733371.01", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746733371.01"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "McCafferty", 
            "givenName": "J", 
            "id": "sg:person.01166177604.78", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166177604.78"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Hodits", 
            "givenName": "R A", 
            "id": "sg:person.0623051072.10", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623051072.10"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Wilton", 
            "givenName": "J", 
            "id": "sg:person.01307775671.15", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307775671.15"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Johnson", 
            "givenName": "K S", 
            "id": "sg:person.01313412431.30", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01313412431.30"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/352530a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001884263", 
              "https://doi.org/10.1038/352530a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/eji.1830230709", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004147441"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.92.5.1254", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004554902"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0959-440x(93)90084-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006922937"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0959-440x(93)90084-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006922937"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0792-779", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007019873", 
              "https://doi.org/10.1038/nbt0792-779"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/nar/21.9.2265", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007512593"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/321522a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007617918", 
              "https://doi.org/10.1038/321522a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/357201a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008614679", 
              "https://doi.org/10.1038/357201a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.1994.56", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009228910", 
              "https://doi.org/10.1038/bjc.1994.56"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.1994.56", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009228910", 
              "https://doi.org/10.1038/bjc.1994.56"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/348552a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009781465", 
              "https://doi.org/10.1038/348552a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1146/annurev.iy.12.040194.002245", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011126452"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0952-7915(93)90018-n", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012453992"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0952-7915(93)90018-n", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012453992"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-1759(85)90044-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013604662"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-1759(85)90044-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013604662"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/332323a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016704652", 
              "https://doi.org/10.1038/332323a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.89.8.3576", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017276811"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/eji.1830200618", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018100538"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.90.9.4141", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019027558"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1006/jmbi.1995.0204", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019785184"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-2836(91)90498-u", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020975126"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.85.16.5879", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021556897"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/352624a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021945431", 
              "https://doi.org/10.1038/352624a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.89.19.9339", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022489440"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-2836(92)90639-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024082698"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/349293a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027225150", 
              "https://doi.org/10.1038/349293a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/eji.1830240409", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028508248"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1006/jmbi.1993.1203", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033055883"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1074/jbc.270.41.24078", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033787907"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng0694-162", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038845506", 
              "https://doi.org/10.1038/ng0694-162"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng0694-162", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038845506", 
              "https://doi.org/10.1038/ng0694-162"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf02787932", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039960827", 
              "https://doi.org/10.1007/bf02787932"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf02787932", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039960827", 
              "https://doi.org/10.1007/bf02787932"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.89.21.10164", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044797140"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/eji.1830220336", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045893431"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-5193(79)90275-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047063231"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0140-6736(92)92294-p", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047952391"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0140-6736(92)92294-p", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047952391"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0140-6736(94)92695-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048159372"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0140-6736(94)92695-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048159372"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-2836(92)90223-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050023212"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0092-8674(86)90746-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051320027"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0161-5890(86)90017-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052512889"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0161-5890(86)90017-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052512889"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.3109/08830189309061696", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052911329"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/hmg/3.6.853", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1059645003"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1081654853", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/j.1460-2075.1993.tb05706.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1082463272"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/j.1460-2075.1994.tb06626.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1082624346"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1082719689", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1996-03", 
        "datePublishedReg": "1996-03-01", 
        "description": "To generate a stable resource from which high affinity human antibodies to any given antigen can be rapidly isolated, functional V-gene segments from 43 non-immunized human donors were used to construct a repertoire of 1.4 x 10(10) single-chain Fv (scFv) fragments displayed on the surface of phage. Fragments were cloned in a phagemid vector, enabling both phage displayed and soluble scFv to be produced without subcloning. A hexahistidine tag has been incorporated to allow rapid purification of scFv by nickel chelate chromatography. This library format reduces the time needed to isolate monoclonal antibody fragments to under two weeks. All of the measured binding affinities show a Kd < 10 nM and off-rates of 10(-3) to 10(-4) s-1, properties usually associated with antibodies from a secondary immune response. The best of these scFvs, an anti-fluorescein antibody (0.3 nM) and an antibody directed against the hapten DTPA (0.8 nM), are the first antibodies with subnanomolar binding affinities to be isolated from a naive library. Antibodies to doxorubicin, which is both immunosuppressive and toxic, as well as a high affinity and high specificity antibody to the steroid hormone oestradiol have been isolated. This work shows that conventional hybridoma technology may be superseded by large phage libraries that are proving to be a stable and reliable source of specific, high affinity human monoclonal antibodies.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1038/nbt0396-309", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1115214", 
            "issn": [
              "1087-0156", 
              "1546-1696"
            ], 
            "name": "Nature Biotechnology", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "3", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "14"
          }
        ], 
        "name": "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library", 
        "pagination": "309", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "6c2ab466e17a44282fea8c2efe67b6923f1a7329a4ebd85cc3fe668aac011b87"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "9630891"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "9604648"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nbt0396-309"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1022704505"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nbt0396-309", 
          "https://app.dimensions.ai/details/publication/pub.1022704505"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-10T17:21", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8672_00000442.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://www.nature.com/articles/nbt0396-309"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nbt0396-309'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nbt0396-309'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nbt0396-309'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nbt0396-309'


     

    This table displays all metadata directly associated to this object as RDF triples.

    325 TRIPLES      21 PREDICATES      88 URIs      37 LITERALS      25 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nbt0396-309 schema:about N0bb9ac022d1c4ad38bb786e30b9370eb
    2 N0ee49a2d59e34167b48e6d203604a38f
    3 N1794b81c47fc4ea8ac50b93d5e25a18f
    4 N24f65026234e4141a558e7880abb52d8
    5 N3c662e4d93de40a8b03d39da3c50b8af
    6 N5093564b07a94dd7aba37c764b3bd8b5
    7 N5633e1ac5c384502a33b33a928a9b75c
    8 N609d618c54a34ca8ace4fa41f38bf151
    9 N60a189e9fbe849c98edeb232dbe94389
    10 N6bdc8d7673c145799bd4c1ce78cff924
    11 N74bb6118947d4f66a9104b49cbbcbc45
    12 Nb2561330783846d8b418bfa9eeb01180
    13 Nc23376512a664a0fb6d4dddc0baac2e9
    14 Nc70fb968a50d4c3a978d0141e2196e19
    15 Ndd8f753f41f04fccb0ce852c4f9b2c3b
    16 Nf9d73ae0863248c792dab55ac0c1cc99
    17 anzsrc-for:11
    18 anzsrc-for:1107
    19 schema:author Nf88b15cc586a4dc6aa4091d169c6bcf9
    20 schema:citation sg:pub.10.1007/bf02787932
    21 sg:pub.10.1038/321522a0
    22 sg:pub.10.1038/332323a0
    23 sg:pub.10.1038/348552a0
    24 sg:pub.10.1038/349293a0
    25 sg:pub.10.1038/352530a0
    26 sg:pub.10.1038/352624a0
    27 sg:pub.10.1038/357201a0
    28 sg:pub.10.1038/bjc.1994.56
    29 sg:pub.10.1038/nbt0792-779
    30 sg:pub.10.1038/ng0694-162
    31 https://app.dimensions.ai/details/publication/pub.1081654853
    32 https://app.dimensions.ai/details/publication/pub.1082719689
    33 https://doi.org/10.1002/eji.1830200618
    34 https://doi.org/10.1002/eji.1830220336
    35 https://doi.org/10.1002/eji.1830230709
    36 https://doi.org/10.1002/eji.1830240409
    37 https://doi.org/10.1002/j.1460-2075.1993.tb05706.x
    38 https://doi.org/10.1002/j.1460-2075.1994.tb06626.x
    39 https://doi.org/10.1006/jmbi.1993.1203
    40 https://doi.org/10.1006/jmbi.1995.0204
    41 https://doi.org/10.1016/0022-1759(85)90044-4
    42 https://doi.org/10.1016/0022-2836(91)90498-u
    43 https://doi.org/10.1016/0022-2836(92)90223-7
    44 https://doi.org/10.1016/0022-2836(92)90639-2
    45 https://doi.org/10.1016/0022-5193(79)90275-3
    46 https://doi.org/10.1016/0092-8674(86)90746-4
    47 https://doi.org/10.1016/0140-6736(92)92294-p
    48 https://doi.org/10.1016/0161-5890(86)90017-9
    49 https://doi.org/10.1016/0952-7915(93)90018-n
    50 https://doi.org/10.1016/0959-440x(93)90084-x
    51 https://doi.org/10.1016/s0140-6736(94)92695-6
    52 https://doi.org/10.1073/pnas.85.16.5879
    53 https://doi.org/10.1073/pnas.89.19.9339
    54 https://doi.org/10.1073/pnas.89.21.10164
    55 https://doi.org/10.1073/pnas.89.8.3576
    56 https://doi.org/10.1073/pnas.90.9.4141
    57 https://doi.org/10.1073/pnas.92.5.1254
    58 https://doi.org/10.1074/jbc.270.41.24078
    59 https://doi.org/10.1093/hmg/3.6.853
    60 https://doi.org/10.1093/nar/21.9.2265
    61 https://doi.org/10.1146/annurev.iy.12.040194.002245
    62 https://doi.org/10.3109/08830189309061696
    63 schema:datePublished 1996-03
    64 schema:datePublishedReg 1996-03-01
    65 schema:description To generate a stable resource from which high affinity human antibodies to any given antigen can be rapidly isolated, functional V-gene segments from 43 non-immunized human donors were used to construct a repertoire of 1.4 x 10(10) single-chain Fv (scFv) fragments displayed on the surface of phage. Fragments were cloned in a phagemid vector, enabling both phage displayed and soluble scFv to be produced without subcloning. A hexahistidine tag has been incorporated to allow rapid purification of scFv by nickel chelate chromatography. This library format reduces the time needed to isolate monoclonal antibody fragments to under two weeks. All of the measured binding affinities show a Kd < 10 nM and off-rates of 10(-3) to 10(-4) s-1, properties usually associated with antibodies from a secondary immune response. The best of these scFvs, an anti-fluorescein antibody (0.3 nM) and an antibody directed against the hapten DTPA (0.8 nM), are the first antibodies with subnanomolar binding affinities to be isolated from a naive library. Antibodies to doxorubicin, which is both immunosuppressive and toxic, as well as a high affinity and high specificity antibody to the steroid hormone oestradiol have been isolated. This work shows that conventional hybridoma technology may be superseded by large phage libraries that are proving to be a stable and reliable source of specific, high affinity human monoclonal antibodies.
    66 schema:genre research_article
    67 schema:inLanguage en
    68 schema:isAccessibleForFree false
    69 schema:isPartOf N4baa87f638274d8884490f8a831591d8
    70 Nb7444cdeb531444b87749ed38c3b294f
    71 sg:journal.1115214
    72 schema:name Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library
    73 schema:pagination 309
    74 schema:productId N008ee747f8b6402197607d500461e70d
    75 N48d4045a826c46689839a870984d58fa
    76 N73a356b6be704feaa6767dfbaf3773ad
    77 Ne4864846dfa64b87ad6619e1f58e3ec9
    78 Neb4caeeb415747f2a4c96aabc370b410
    79 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022704505
    80 https://doi.org/10.1038/nbt0396-309
    81 schema:sdDatePublished 2019-04-10T17:21
    82 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    83 schema:sdPublisher Ncbd49a98d62348e79edc1bc69d587931
    84 schema:url https://www.nature.com/articles/nbt0396-309
    85 sgo:license sg:explorer/license/
    86 sgo:sdDataset articles
    87 rdf:type schema:ScholarlyArticle
    88 N008ee747f8b6402197607d500461e70d schema:name doi
    89 schema:value 10.1038/nbt0396-309
    90 rdf:type schema:PropertyValue
    91 N0bb9ac022d1c4ad38bb786e30b9370eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    92 schema:name In Vitro Techniques
    93 rdf:type schema:DefinedTerm
    94 N0ee49a2d59e34167b48e6d203604a38f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    95 schema:name Oligodeoxyribonucleotides
    96 rdf:type schema:DefinedTerm
    97 N1794b81c47fc4ea8ac50b93d5e25a18f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    98 schema:name Estradiol
    99 rdf:type schema:DefinedTerm
    100 N24f65026234e4141a558e7880abb52d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    101 schema:name Antibodies, Monoclonal
    102 rdf:type schema:DefinedTerm
    103 N3c662e4d93de40a8b03d39da3c50b8af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    104 schema:name Molecular Sequence Data
    105 rdf:type schema:DefinedTerm
    106 N48d4045a826c46689839a870984d58fa schema:name pubmed_id
    107 schema:value 9630891
    108 rdf:type schema:PropertyValue
    109 N4baa87f638274d8884490f8a831591d8 schema:volumeNumber 14
    110 rdf:type schema:PublicationVolume
    111 N5093564b07a94dd7aba37c764b3bd8b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Humans
    113 rdf:type schema:DefinedTerm
    114 N5384f072cacd440399362f18f99826f8 rdf:first sg:person.01057320671.34
    115 rdf:rest Na415eab0859149d0973e34105034b432
    116 N5633e1ac5c384502a33b33a928a9b75c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Base Sequence
    118 rdf:type schema:DefinedTerm
    119 N5eea3c4710b7429e973dce93a013a348 rdf:first sg:person.0700373631.57
    120 rdf:rest N5384f072cacd440399362f18f99826f8
    121 N609d618c54a34ca8ace4fa41f38bf151 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    122 schema:name Kinetics
    123 rdf:type schema:DefinedTerm
    124 N60a189e9fbe849c98edeb232dbe94389 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Antibody Specificity
    126 rdf:type schema:DefinedTerm
    127 N6bdc8d7673c145799bd4c1ce78cff924 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Amino Acid Sequence
    129 rdf:type schema:DefinedTerm
    130 N73a356b6be704feaa6767dfbaf3773ad schema:name dimensions_id
    131 schema:value pub.1022704505
    132 rdf:type schema:PropertyValue
    133 N74bb6118947d4f66a9104b49cbbcbc45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Cloning, Molecular
    135 rdf:type schema:DefinedTerm
    136 N7d287fa3c9e14f088c67537d059ee41c rdf:first sg:person.01313412431.30
    137 rdf:rest rdf:nil
    138 N8efba274a31b4fcd97584ca6d12a6c24 rdf:first sg:person.0632260431.54
    139 rdf:rest N5eea3c4710b7429e973dce93a013a348
    140 N97df404185d2448583ad4853ee3ef425 rdf:first sg:person.0746733371.01
    141 rdf:rest Nc9f9fa280c714de5a16d012a805ebbe3
    142 Na415eab0859149d0973e34105034b432 rdf:first sg:person.01014622231.24
    143 rdf:rest N97df404185d2448583ad4853ee3ef425
    144 Nb2561330783846d8b418bfa9eeb01180 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Biotechnology
    146 rdf:type schema:DefinedTerm
    147 Nb7444cdeb531444b87749ed38c3b294f schema:issueNumber 3
    148 rdf:type schema:PublicationIssue
    149 Nc23376512a664a0fb6d4dddc0baac2e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Bacteriophages
    151 rdf:type schema:DefinedTerm
    152 Nc70fb968a50d4c3a978d0141e2196e19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Doxorubicin
    154 rdf:type schema:DefinedTerm
    155 Nc9f9fa280c714de5a16d012a805ebbe3 rdf:first sg:person.01166177604.78
    156 rdf:rest Nf85d2483eb184af4a9b6b7d110fd6139
    157 Nca5177334cf44f70b38c2e041fac5ec1 rdf:first sg:person.01307775671.15
    158 rdf:rest N7d287fa3c9e14f088c67537d059ee41c
    159 Ncbd49a98d62348e79edc1bc69d587931 schema:name Springer Nature - SN SciGraph project
    160 rdf:type schema:Organization
    161 Ndd8f753f41f04fccb0ce852c4f9b2c3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Antibody Affinity
    163 rdf:type schema:DefinedTerm
    164 Ne4864846dfa64b87ad6619e1f58e3ec9 schema:name nlm_unique_id
    165 schema:value 9604648
    166 rdf:type schema:PropertyValue
    167 Neb4caeeb415747f2a4c96aabc370b410 schema:name readcube_id
    168 schema:value 6c2ab466e17a44282fea8c2efe67b6923f1a7329a4ebd85cc3fe668aac011b87
    169 rdf:type schema:PropertyValue
    170 Nf85d2483eb184af4a9b6b7d110fd6139 rdf:first sg:person.0623051072.10
    171 rdf:rest Nca5177334cf44f70b38c2e041fac5ec1
    172 Nf88b15cc586a4dc6aa4091d169c6bcf9 rdf:first sg:person.0743122630.97
    173 rdf:rest N8efba274a31b4fcd97584ca6d12a6c24
    174 Nf9d73ae0863248c792dab55ac0c1cc99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Immunoglobulin Fragments
    176 rdf:type schema:DefinedTerm
    177 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    178 schema:name Medical and Health Sciences
    179 rdf:type schema:DefinedTerm
    180 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    181 schema:name Immunology
    182 rdf:type schema:DefinedTerm
    183 sg:journal.1115214 schema:issn 1087-0156
    184 1546-1696
    185 schema:name Nature Biotechnology
    186 rdf:type schema:Periodical
    187 sg:person.01014622231.24 schema:familyName Pope
    188 schema:givenName A R
    189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014622231.24
    190 rdf:type schema:Person
    191 sg:person.01057320671.34 schema:familyName Osbourn
    192 schema:givenName J K
    193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057320671.34
    194 rdf:type schema:Person
    195 sg:person.01166177604.78 schema:familyName McCafferty
    196 schema:givenName J
    197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166177604.78
    198 rdf:type schema:Person
    199 sg:person.01307775671.15 schema:familyName Wilton
    200 schema:givenName J
    201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307775671.15
    202 rdf:type schema:Person
    203 sg:person.01313412431.30 schema:familyName Johnson
    204 schema:givenName K S
    205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01313412431.30
    206 rdf:type schema:Person
    207 sg:person.0623051072.10 schema:familyName Hodits
    208 schema:givenName R A
    209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623051072.10
    210 rdf:type schema:Person
    211 sg:person.0632260431.54 schema:familyName Williams
    212 schema:givenName A J
    213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632260431.54
    214 rdf:type schema:Person
    215 sg:person.0700373631.57 schema:familyName Pritchard
    216 schema:givenName K
    217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700373631.57
    218 rdf:type schema:Person
    219 sg:person.0743122630.97 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
    220 schema:familyName Vaughan
    221 schema:givenName T J
    222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743122630.97
    223 rdf:type schema:Person
    224 sg:person.0746733371.01 schema:familyName Earnshaw
    225 schema:givenName J C
    226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746733371.01
    227 rdf:type schema:Person
    228 sg:pub.10.1007/bf02787932 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039960827
    229 https://doi.org/10.1007/bf02787932
    230 rdf:type schema:CreativeWork
    231 sg:pub.10.1038/321522a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007617918
    232 https://doi.org/10.1038/321522a0
    233 rdf:type schema:CreativeWork
    234 sg:pub.10.1038/332323a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016704652
    235 https://doi.org/10.1038/332323a0
    236 rdf:type schema:CreativeWork
    237 sg:pub.10.1038/348552a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009781465
    238 https://doi.org/10.1038/348552a0
    239 rdf:type schema:CreativeWork
    240 sg:pub.10.1038/349293a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027225150
    241 https://doi.org/10.1038/349293a0
    242 rdf:type schema:CreativeWork
    243 sg:pub.10.1038/352530a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001884263
    244 https://doi.org/10.1038/352530a0
    245 rdf:type schema:CreativeWork
    246 sg:pub.10.1038/352624a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021945431
    247 https://doi.org/10.1038/352624a0
    248 rdf:type schema:CreativeWork
    249 sg:pub.10.1038/357201a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008614679
    250 https://doi.org/10.1038/357201a0
    251 rdf:type schema:CreativeWork
    252 sg:pub.10.1038/bjc.1994.56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009228910
    253 https://doi.org/10.1038/bjc.1994.56
    254 rdf:type schema:CreativeWork
    255 sg:pub.10.1038/nbt0792-779 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007019873
    256 https://doi.org/10.1038/nbt0792-779
    257 rdf:type schema:CreativeWork
    258 sg:pub.10.1038/ng0694-162 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038845506
    259 https://doi.org/10.1038/ng0694-162
    260 rdf:type schema:CreativeWork
    261 https://app.dimensions.ai/details/publication/pub.1081654853 schema:CreativeWork
    262 https://app.dimensions.ai/details/publication/pub.1082719689 schema:CreativeWork
    263 https://doi.org/10.1002/eji.1830200618 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018100538
    264 rdf:type schema:CreativeWork
    265 https://doi.org/10.1002/eji.1830220336 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045893431
    266 rdf:type schema:CreativeWork
    267 https://doi.org/10.1002/eji.1830230709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004147441
    268 rdf:type schema:CreativeWork
    269 https://doi.org/10.1002/eji.1830240409 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028508248
    270 rdf:type schema:CreativeWork
    271 https://doi.org/10.1002/j.1460-2075.1993.tb05706.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1082463272
    272 rdf:type schema:CreativeWork
    273 https://doi.org/10.1002/j.1460-2075.1994.tb06626.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1082624346
    274 rdf:type schema:CreativeWork
    275 https://doi.org/10.1006/jmbi.1993.1203 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033055883
    276 rdf:type schema:CreativeWork
    277 https://doi.org/10.1006/jmbi.1995.0204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019785184
    278 rdf:type schema:CreativeWork
    279 https://doi.org/10.1016/0022-1759(85)90044-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013604662
    280 rdf:type schema:CreativeWork
    281 https://doi.org/10.1016/0022-2836(91)90498-u schema:sameAs https://app.dimensions.ai/details/publication/pub.1020975126
    282 rdf:type schema:CreativeWork
    283 https://doi.org/10.1016/0022-2836(92)90223-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050023212
    284 rdf:type schema:CreativeWork
    285 https://doi.org/10.1016/0022-2836(92)90639-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024082698
    286 rdf:type schema:CreativeWork
    287 https://doi.org/10.1016/0022-5193(79)90275-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047063231
    288 rdf:type schema:CreativeWork
    289 https://doi.org/10.1016/0092-8674(86)90746-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051320027
    290 rdf:type schema:CreativeWork
    291 https://doi.org/10.1016/0140-6736(92)92294-p schema:sameAs https://app.dimensions.ai/details/publication/pub.1047952391
    292 rdf:type schema:CreativeWork
    293 https://doi.org/10.1016/0161-5890(86)90017-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052512889
    294 rdf:type schema:CreativeWork
    295 https://doi.org/10.1016/0952-7915(93)90018-n schema:sameAs https://app.dimensions.ai/details/publication/pub.1012453992
    296 rdf:type schema:CreativeWork
    297 https://doi.org/10.1016/0959-440x(93)90084-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1006922937
    298 rdf:type schema:CreativeWork
    299 https://doi.org/10.1016/s0140-6736(94)92695-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048159372
    300 rdf:type schema:CreativeWork
    301 https://doi.org/10.1073/pnas.85.16.5879 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021556897
    302 rdf:type schema:CreativeWork
    303 https://doi.org/10.1073/pnas.89.19.9339 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022489440
    304 rdf:type schema:CreativeWork
    305 https://doi.org/10.1073/pnas.89.21.10164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044797140
    306 rdf:type schema:CreativeWork
    307 https://doi.org/10.1073/pnas.89.8.3576 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017276811
    308 rdf:type schema:CreativeWork
    309 https://doi.org/10.1073/pnas.90.9.4141 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019027558
    310 rdf:type schema:CreativeWork
    311 https://doi.org/10.1073/pnas.92.5.1254 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004554902
    312 rdf:type schema:CreativeWork
    313 https://doi.org/10.1074/jbc.270.41.24078 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033787907
    314 rdf:type schema:CreativeWork
    315 https://doi.org/10.1093/hmg/3.6.853 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059645003
    316 rdf:type schema:CreativeWork
    317 https://doi.org/10.1093/nar/21.9.2265 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007512593
    318 rdf:type schema:CreativeWork
    319 https://doi.org/10.1146/annurev.iy.12.040194.002245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011126452
    320 rdf:type schema:CreativeWork
    321 https://doi.org/10.3109/08830189309061696 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052911329
    322 rdf:type schema:CreativeWork
    323 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
    324 schema:name Cambridge Antibody Technology Ltd., Unit B3, Melbourn, Cambridgeshire, U.K.
    325 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...